Safety Study of Treatment of Leg Fractures

Overview

This study evaluates the safety of the EVOS SMALL Plating system in patients who have a fracture of the tibia requiring surgery.

Full Title of Study: “Multicenter, Post-market Observational Study Evaluating Safety and Efficacy of the EVOS SMALL Plating System for the Treatment of Lower Extremity Fractures”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: March 24, 2020

Detailed Description

This is a multicenter, prospective, post-marketing, observational, case series study to evaluate the safety and efficacy of the EVOS SMALL Plating System in subjects with proximal or distal (pilon or ankle) tibial fractures. Subjects will be recruited in the hospital emergency room or surgical department, at the point of identification of the need for ORIF surgery, and the decision is made to use the EVOS SMALL Plating System. The choice of medical and surgical treatment will be made independently by the Investigator in the regular course of practice and will not be influenced by this study protocol. Approximately 100 subjects will be enrolled in order to ensure at least 90 evaluable subjects, with a minimum of 45 evaluable subjects having either a) proximal or b) distal tibial fractures. Safety monitoring will include documentation device- and surgery-related AEs. Efficacy will be monitored by assessment of post-operative fracture resolution according to standard radiological practice (X-rays), clinical complications, reoperation rate, DRI, EQ-5D-5L, and pain VAS.

Arms, Groups and Cohorts

  • Study Treatment
    • EVOS SMALL PLating System

Clinical Trial Outcome Measures

Primary Measures

  • Reoperation rate for any reason of the lower extremity fractures treated operatively with the EVOS SMALL Plating System
    • Time Frame: 1 year

Secondary Measures

  • Number of adverse events
    • Time Frame: 1 year
  • Disability Rating Index (DRI)
    • Time Frame: 1 year
    • Change in subject’s ease of mobility as marked on a 100 mm line by subject with the far left indicating “without difficulty” and the far right indicating “not at all”
  • EuroQoL-5D Questionnaire
    • Time Frame: 1 year
    • Change in quality of life from baseline to one year postoperatively by answering quality of life questions on a 1-5 scale with 1 representing “never” and 5 representing “always”
  • Pain using visual analog scale (VAS)
    • Time Frame: 1 year
    • level of pain as marked on a 100 mm line by subject with 0mm representing “no pain” and 100mm representing “worst possible pain”
  • Number of complications relating to surgery
    • Time Frame: 1 year
  • Number of hospital readmissions for any reason
    • Time Frame: 1 year

Participating in This Clinical Trial

Inclusion Criteria

1. Male or female subject who is 18 years of age or older at the time of signing the informed consent. 2. Subject provides an Institutional Review Board (IRB)-approved informed consent. The subject must have the physical and mental capacity to provide informed consent for him/herself. 3. Subject has experienced proximal tibial fracture (OTA Type 41 A-C) or distal tibial fracture (OTA 43 Type A-C) with or without fibular/malleolar involvement (OTA 44 A-C) and are scheduled for ORIF using the EVOS SMALL Plating System. 4. Subject is willing and able to attend all study visits including 1 year post-operative follow-up. Exclusion Criteria:

1. Subject has contraindications or hypersensitivity to the use of the EVOS SMALL Plating System or its components (316L stainless steel). 2. Subject has a physical condition that, in the opinion of the Investigator, would preclude adequate implant support or retard healing, such as blood supply impairment, insufficient bone quality or quantity, previous infection, obesity, severe bow or gross bony distortion of the tibia, as detailed in the IFU. 3. Subject has, in the opinion of the Investigator, an emotional or neurologic condition that precludes cooperation and compliance with the rehabilitation regimen. 4. Subject is currently in another investigational drug, biologic, or device study or has been treated with an investigational product within the last 30 days. 5. Subject is known to be at risk for loss to follow-up, or failure to return for scheduled visits.

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Smith & Nephew, Inc.
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Rachel Nelson, Study Chair, Smith & Nephew, Inc.

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.